Industry
Biotechnology
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 26, 2024 | 7:03 am
Portfolio Pulse from Benzinga Newsdesk
March 22, 2024 | 3:13 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 5:59 am
Portfolio Pulse from Benzinga Newsdesk
December 27, 2023 | 4:45 pm
Portfolio Pulse from Benzinga Insights
December 14, 2023 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
December 14, 2023 | 2:11 pm
Portfolio Pulse from Benzinga Newsdesk
November 15, 2023 | 12:05 pm
Portfolio Pulse from Benzinga Insights
November 14, 2023 | 1:23 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 2:06 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.